Pioglitazone Induced Reversible Pancytopenia

Karakurt F., Kargili A., KASAPOĞLU B.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, cilt.118, sa.2, ss.96-97, 2010 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 118 Sayı: 2
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1055/s-0029-1234065
  • Dergi Adı: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.96-97
  • Anahtar Kelimeler: pioglitazone, diabetes mellitus type 2, pancytopenia, THIAZOLIDINEDIONES
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.